• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将基因检测转化为临床和公共卫生实践面临的挑战。

Challenges of translating genetic tests into clinical and public health practice.

作者信息

Rogowski Wolf H, Grosse Scott D, Khoury Muin J

机构信息

Helmholtz Center Munich, German Research Center for Environmental Health, Ingolstädter Landstrasse 1, Neuherberg 85764, Germany.

出版信息

Nat Rev Genet. 2009 Jul;10(7):489-95. doi: 10.1038/nrg2606.

DOI:10.1038/nrg2606
PMID:19506575
Abstract

Research in genetics and genomics has led to an expanding list of molecular genetic tests, which are increasingly entering health care systems. However, the evidence surrounding the benefits and harms of these tests is frequently weak. Here we present the main challenges to the successful translation of new research findings about genotype-phenotype associations into clinical practice. We discuss the means to achieve an accelerated translation research agenda that is conducted in a reasonable, fair and efficient manner.

摘要

遗传学和基因组学研究催生了越来越多的分子遗传学检测方法,这些检测方法正日益进入医疗保健系统。然而,关于这些检测方法利弊的证据往往并不充分。在此,我们阐述了将有关基因型-表型关联的新研究成果成功转化为临床实践所面临的主要挑战。我们探讨了实现以合理、公平且高效的方式开展加速转化研究议程的方法。

相似文献

1
Challenges of translating genetic tests into clinical and public health practice.将基因检测转化为临床和公共卫生实践面临的挑战。
Nat Rev Genet. 2009 Jul;10(7):489-95. doi: 10.1038/nrg2606.
2
Integrating Genomics into Healthcare: A Global Responsibility.将基因组学融入医疗保健:全球的责任。
Am J Hum Genet. 2019 Jan 3;104(1):13-20. doi: 10.1016/j.ajhg.2018.11.014.
3
Genomics moves into the clinic.基因组学走进临床。
Biotechniques. 2012 Feb;52(2):73-6. doi: 10.2144/000113806.
4
Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges.低收入和中等收入国家的转化基因组学:机遇与挑战
Public Health Genomics. 2015;18(4):242-7. doi: 10.1159/000433518. Epub 2015 Jun 26.
5
Gene sequencing leaves the laboratory.基因测序走出实验室。
Nature. 2013 Feb 21;494(7437):290-1. doi: 10.1038/494290a.
6
Genomic medicine: genetic variation and its impact on the future of health care.基因组医学:基因变异及其对医疗保健未来的影响。
Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1543-50. doi: 10.1098/rstb.2005.1683.
7
Quantitative genetics in the age of genomics.基因组学时代的数量遗传学。
Theor Popul Biol. 2001 May;59(3):175-84. doi: 10.1006/tpbi.2001.1512.
8
Implementation of genomic medicine in a health care delivery system: a value proposition?在医疗保健系统中实施基因组医学:一个价值主张?
Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):112-6. doi: 10.1002/ajmg.c.31392. Epub 2014 Mar 11.
9
[Genetics, genomics and medicine].[遗传学、基因组学与医学]
Presse Med. 2012 Jan;41(1):1-2. doi: 10.1016/j.lpm.2011.09.003. Epub 2011 Oct 12.
10
Genomics shifts focus to rare diseases.基因组学将重点转向罕见病。
Nature. 2009 Sep 24;461(7263):458. doi: 10.1038/461458a.

引用本文的文献

1
[Genomics in Public Health Scientific evidence and prospects for integration in the prevention practice].[公共卫生中的基因组学:科学证据及整合至预防实践的前景]
J Prev Med Hyg. 2023 Jan 13;63(3 Suppl 2):E1-E29. doi: 10.15167/2421-4248/jpmh2022.63.3s2. eCollection 2023 Mar.
2
A Focus Group Study of Perceptions of Genetic Risk Disclosure in Members of the Public in Sweden: "I'll Phone the Five Closest Ones, but What Happens to the Other Ten?".瑞典公众对基因风险披露认知的焦点小组研究:“我会给最亲近的五个人打电话,但另外十个人怎么办?”
J Pers Med. 2021 Nov 12;11(11):1191. doi: 10.3390/jpm11111191.
3
Clinical outcomes and temporal trends of immunological and non-immunological rare diseases in adult kidney transplant.

本文引用的文献

1
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.评估医疗保健中的成本效益:50,000 美元/QALY 阈值的历史。
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.
2
Population screening for genetic disorders in the 21st century: evidence, economics, and ethics.21世纪遗传性疾病的群体筛查:证据、经济学与伦理学
Public Health Genomics. 2010;13(2):106-15. doi: 10.1159/000226594. Epub 2009 Jun 29.
3
The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study.
成人肾移植中免疫性和非免疫性罕见病的临床结果和时间趋势。
BMC Nephrol. 2021 Nov 17;22(1):386. doi: 10.1186/s12882-021-02571-z.
4
[The molecular tumor board].[分子肿瘤学专家组]
Chirurg. 2021 Nov;92(11):1011-1015. doi: 10.1007/s00104-021-01487-6.
5
Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.弥合个性化医疗价值评估中的差距:对跨利益相关者和科学学科的结果指标需求的综述
Public Health Genomics. 2019;22(1-2):16-24. doi: 10.1159/000501974. Epub 2019 Aug 27.
6
The Evolution of Public Health Genomics: Exploring Its Past, Present, and Future.公共卫生基因组学的演变:探索其过去、现在和未来
Front Public Health. 2018 Sep 4;6:247. doi: 10.3389/fpubh.2018.00247. eCollection 2018.
7
The economic case for precision medicine.精准医疗的经济学依据。
Expert Rev Precis Med Drug Dev. 2018 Jan 8;3(1):1-9. doi: 10.1080/23808993.2018.1421858. eCollection 2018.
8
Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.哪些林奇综合征筛查方案可以在“现实世界”中实施?一项经济评估的系统综述。
Genet Med. 2018 Oct;20(10):1131-1144. doi: 10.1038/gim.2017.244. Epub 2018 Jan 4.
9
Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.罕见肾脏疾病的共同要素:KDIGO(改善全球肾脏病预后组织)争议会议的结论。
Kidney Int. 2017 Oct;92(4):796-808. doi: 10.1016/j.kint.2017.06.018.
10
Risk Prediction Modeling on Family-Based Sequencing Data Using a Random Field Method.基于家庭测序数据的随机场方法风险预测建模
Genetics. 2017 Sep;207(1):63-73. doi: 10.1534/genetics.117.199752. Epub 2017 Jul 5.
德国遗传性血色素沉着症筛查的成本效益:一项重塑研究。
Med Decis Making. 2009 Mar-Apr;29(2):224-38. doi: 10.1177/0272989X08327112. Epub 2009 Jan 30.
4
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.EGAPP补充证据审查:旨在降低林奇综合征发病率和死亡率的DNA检测策略
Genet Med. 2009 Jan;11(1):42-65. doi: 10.1097/GIM.0b013e31818fa2db.
5
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.EGAPP工作组的建议:针对新诊断的结直肠癌患者的基因检测策略,旨在降低亲属患林奇综合征的发病率和死亡率。
Genet Med. 2009 Jan;11(1):35-41. doi: 10.1097/GIM.0b013e31818fa2ff.
6
An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.直接面向消费者的个人基因组检测的一个不良副作用:侵占医疗公共资源。
JAMA. 2008 Dec 10;300(22):2669-71. doi: 10.1001/jama.2008.803.
7
Closing the evidence gap in the use of emerging testing technologies in clinical practice.弥合临床实践中新兴检测技术应用方面的证据差距。
JAMA. 2008 Dec 3;300(21):2542-4. doi: 10.1001/jama.2008.754.
8
Prioritizing future research on off-label prescribing: results of a quantitative evaluation.确定非标签用药未来研究的优先次序:定量评估结果
Pharmacotherapy. 2008 Dec;28(12):1443-52. doi: 10.1592/phco.28.12.1443.
9
The evidence dilemma in genomic medicine.基因组医学中的证据困境。
Health Aff (Millwood). 2008 Nov-Dec;27(6):1600-11. doi: 10.1377/hlthaff.27.6.1600.
10
Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis.评估基因检测结果的经济学方法:超越成本效益分析
Genet Med. 2008 Sep;10(9):648-54. doi: 10.1097/gim.0b013e3181837217.